Last reviewed · How we verify
NCT05940272
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
NA trial testing Hematolo-GIST Training in Lymphoma, B-Cell in 48 participants. Currently enrolling.
3 July 2028
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 48 |
| Start date | 3 July 2023 |
| Primary completion | 3 July 2028 |
| Estimated completion | 3 July 2028 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Hematolo-GIST Training
- Participants Appointment
Conditions studied
- Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →
- Lymphoma — all drugs for Lymphoma →
- Large-cell Lymphoma — all drugs for Large-cell Lymphoma →
- Large B-cell Lymphoma — all drugs for Large B-cell Lymphoma →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Lymphoma, B-Cell or Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05940272
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphoma, B-Cell
Currently open trials in the same condition.
- NCT06850285 — CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma · NA · recruiting
- NCT06954805 — Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) · Phase 2 · recruiting
- NCT06609304 — Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · Phase 4 · recruiting
- NCT06866873 — CD-19 CAR-T Cell for Pediatric ALL or Lymphoma · NA · recruiting
- NCT06381830 — Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05940272 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 9 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05940272.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing